Elafin Myocardial Protection from Ischaemia RepErfusion injury: A randomised trial to investigate the effect of Elafin on myocardial injury and inflammation in coronary artery bypass surgery During coronary artery bypass graft surgery, the myocardium receives an immediate ischaemic insult, exacerbated by post-ischaemic inflammatory responses following reperfusion that lead to increased myocardial injury. Elafin is a potent endogenous anti-elastase with wide ranging anti-inflammatory properties that inhibit destructive post-ischaemic inflammatory pathways. The aim of the study was to see if elafin would reduce perioperative ischaemic myocardial injury and systemic inflammation in elective coronary artery bypass graft surgery and thus improve patient outcome. Image Chief Investigator: Dr Peter Henriksen Number and location of participating sites (by region/ country): Edinburgh (single centre) EudraCT number: 2010-019527-58 ISRCTN number: ISRCTN82061264 Funder: Medical Research Council and Chest Heart and Stroke, Scotland Start and End date of grant award: Dec 2010 - Sept 2014 Current Status: Awaiting publication Contact details : Sponsor: ACCORD Chief Investigator: Dr Peter Henriksen, Edinburgh Heart Centre, Royal Infirmary of Edinburgh. Trial manager: Ms Kat Oatey, Email: k.oatey@ed.ac.uk ECTU Involvement: Trial management, Statistics, Data base and randomisation service. This article was published on 2024-09-24
